Product Description
Casopitant is a novel NK1 receptor antagonist and second in the class of antiemetics that acts to antagonise the emetogenic effect of substance P. Casopitant has now completed phase III trials for prevention of CINV. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697542/)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Other|Colorectal Cancer|Oncology Unspecified|Lung Cancer
Phase 2: Depressive Disorder, Major|Spinal Cord Injuries|Insomnia|Overactive Bladder|Urinary Incontinence|Fibromyalgia|Enuresis|Anesthesia Related|Oncology Unspecified|Other|Dyspepsia
Phase 1: Healthy Volunteers|Oncology Unspecified|Kidney Diseases|Phobia, Social
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00358813 |
NKT102783 | P1 |
Completed |
Kidney Diseases |
2008-08-22 |
2019-03-21 |
Treatments |
|
NCT00440128 |
NKV100781 | P1 |
Completed |
Oncology Unspecified |
2008-07-17 |
2019-03-21 |
Treatments |
|
NCT00511823 |
NKV110483 | P1 |
Completed |
Healthy Volunteers |
2007-09-21 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT00460707 |
NKV109990 | P1 |
Completed |
Healthy Volunteers |
2007-08-27 |
2019-03-21 |
Treatments |
|
NCT00437229 |
NKV100787 | P1 |
Completed |
Healthy Volunteers |
2007-05-15 |
2024-10-16 |
Primary Endpoints|Treatments |
|
NCT00405080 |
Casopitant | P1 |
Completed |
Healthy Volunteers |
2007-01-05 |
2019-03-21 |
||
NCT00404274 |
NKV105097 | P1 |
Completed |
Healthy Volunteers |
2007-03-18 |
2019-03-21 |
Treatments |
|
NCT00404378 |
GW679769 | P1 |
Completed |
Healthy Volunteers |
2007-01-05 |
2019-03-21 |
Treatments |
|
NCT00359177 |
NKT102785 | P1 |
Completed |
Healthy Volunteers |
2006-10-12 |
2019-03-21 |
Treatments |
|
2005-004889-17 |
2005-004889-17 | P2 |
Completed |
Insomnia |
2007-07-13 |
2022-03-12 |
Treatments |
|
NCT00354809 |
MAD105516 | P2 |
Completed |
Insomnia |
2007-07-01 |
2019-03-21 |
Treatments |
|
2006-001877-13 |
2006-001877-13 | P2 |
Terminated |
Depressive Disorder, Major |
2007-06-24 |
2022-03-12 |
Treatments |
|
NCT00280436 |
MAD105514 | P2 |
Completed |
Insomnia |
2007-03-01 |
2019-03-21 |
Treatments |
|
NCT00280423 |
MAD103894 | P2 |
Completed |
Insomnia |
2007-02-01 |
2019-03-21 |
Treatments |
|
NCT00332319 |
NKB104846 | P2 |
Terminated |
Enuresis|Spinal Cord Injuries|Overactive Bladder|Urinary Incontinence |
2007-02-01 |
2019-03-21 |
Treatments |
|
NCT00321477 |
NKB105022 | P2 |
Completed |
Enuresis|Urinary Incontinence|Overactive Bladder |
2007-02-01 |
2019-03-21 |
Treatments |
|
2005-001010-41 |
2005-001010-41 | P2 |
Terminated |
Fibromyalgia |
2007-01-11 |
2022-03-12 |
Treatments |
|
NCT00891761 |
NCT00891761 | P3 |
Withdrawn |
Lung Cancer |
2010-07-01 |
2024-10-16 |
||
NCT00601172 |
NKV110721 | P3 |
Completed |
Colorectal Cancer |
2009-04-13 |
2024-10-16 |
Primary Endpoints|Treatments |
|
2007-005169-36 |
2007-005169-36 | P3 |
Completed |
Colorectal Cancer |
2009-04-07 |
2022-03-12 |
Treatments |
|
NCT00431236 |
NKV102551 | P3 |
Completed |
Oncology Unspecified |
2007-10-09 |
2024-10-16 |
||
2006-002033-21 |
2006-002033-21 | P3 |
Completed |
Oncology Unspecified |
2007-10-09 |
2022-03-12 |
Treatments |
|
NCT00366834 |
NKV102549 | P3 |
Completed |
Other |
2007-10-01 |
2024-10-16 |
||
2006-000781-37 |
2006-000781-37 | P3 |
Completed |
Other |
2007-08-24 |
2025-07-09 |
Treatments |
|
2005-005855-16 |
2005-005855-16 | P3 |
Completed |
Unknown |
2006-11-20 |
2022-03-12 |
Treatments |